GSK hands back failed muscular dystrophy drug to Prosensa

LONDON Mon Jan 13, 2014 8:32am EST

• Tweet
• Share this
• Email
• Print

The signage for the GlaxoSmithKline building is pictured in Hounslow, west London June 18, 2013.

Credit: Reuters/Luke MacGregor

LONDON (Reuters) - GlaxoSmithKline has handed back rights to an experimental drug for Duchenne muscular dystrophy to Dutch biotech firm Prosensa after it failed last year in a critical clinical trial.

Britain's biggest drugmaker said on Monday that Prosensa would now have full and unencumbered rights to drisapersen. The move marks the termination of a 2009 collaboration agreement between the two firms.

Hopes for the drug slumped last September when it did not show a statistically significant improvement in the distance that patients could walk in six minutes compared with a placebo in a final-stage Phase III test run by GSK.

(Reporting by Ben Hirschler; Editing by Greg Mahlich)

• Tweet this
• Link this
• Share this
• Digg this
• Email
• Print
• Reprints

We welcome comments that advance the story through relevant opinion, anecdotes, links and data. If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links. Views expressed in the comments do not represent those of Reuters. For more information on our comment policy, see http://blogs.reuters.com/fulldisclosure/2010/09/27/toward-a-more-thoughtful-conversation-on-stories/

Comments (0)

Be the first to comment on reuters.com.

Add yours using the box above.

Source : http://feeds.reuters.com/~r/reuters/healthNews/~3/b9aEHVQS26k/story01.htm